Press Releases :: Nighthawk Biosciences, Inc. (NHWK)

Jan 21, 2020 4:05pm EST

Heat Biologics, Inc. Announces Closing of $7,000,000 Public Offering

Jan 16, 2020 9:50am EST

Heat Biologics, Inc. Prices $7,000,000 Public Offering

Dec 16, 2019 7:00am EST

Heat Biologics Announces First Patient Dosed in the First Phase 1 Trial of HS-130

Nov 20, 2019 8:00am EST

Heat Biologics Announces Additional Positive Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients

Nov 18, 2019 8:00am EST

Heat Biologics Announces Additional Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients at AACR Tumor Immunology and Immunotherapy Conference

Nov 15, 2019 8:30am EST

Heat Biologics Reports Third Quarter 2019 Results and Provides Corporate Update

Nov 11, 2019 7:00am EST

Heat Biologics Presents Additional Phase 2 Interim Data in Advanced NSCLC Patients at the SITC 34th Annual Meeting

Nov 05, 2019 8:00am EST

Heat Biologics Reports Positive Phase 2 Interim Data in NSCLC Patients Who Previously Failed Checkpoint Inhibitor Treatment

Oct 24, 2019 9:00am EDT

Heat Biologics Announces a Poster Presentation of Updated Top Line Phase 2 Data of HS-110 plus Nivolumab after Checkpoint Inhibitor Treatment Failure in NSCLC Patients at the SITC 34th Annual Meeting

Aug 14, 2019 7:00am EDT

Heat Biologics Reports Second Quarter 2019 Results and Provides Corporate Update

rss_feed News RSS

OUR ECOSYSTEM